Conolidine’s analgesic results stem from its interaction with non-opioid pain pathways. Contrary to opioids, which bind to µ-opioid receptors from the central nervous procedure, conolidine modulates alternate molecular targets. A Science Advances review uncovered that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. By https://buckminsterd136sor1.buyoutblog.com/profile